Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07080567

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Led by Emmanuel Carrera · Updated on 2025-08-12

80

Participants Needed

1

Research Sites

124 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.

CONDITIONS

Official Title

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Informed consent as documented by signature
  • ≥18 years at time of signing of informed consent
  • Acute ischemic stroke.
  • Stroke onset < 7 days from randomization.
  • Contralateral, unilateral, incomplete upper limb paresis, incl. :
  • FMA-UE < 63/66
  • Residual voluntary finger extension (VFE) of > 10 degrees
Not Eligible

You will not qualify if you...

  • Pregnancy/lactation or positive pregnancy test in women of childbearing age
  • Pre-stroke handicap (mRS > 2)
  • Diseases affecting motor function (e.g., Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS))
  • Participation in another study with investigational medicinal product within 30 days preceding and during the present study
  • Enrolment of the investigator, his/her family members, employees, or other dependent persons
  • Known hypersensitivity to Maraviroc, Mannitol, peanuts, or soy
  • History of significant liver disease, hepatitis, elevated liver function tests (> 1.5 upper limit of normal)
  • History of significant renal disease or End Stage Renal Disease/dialysis, acute renal injury, Creatinine Clearance (CrCl < 30ml/min/1.73m2)
  • Patients with cardiovascular comorbidities and risk for orthostatic hypotension
  • HIV infection
  • Concomitant use of strong CYP3A4 inhibitors or inducers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Geneva University Hospital

Geneva, Switzerland

Actively Recruiting

Loading map...

Research Team

E

Emmanuel Carrera, MD

CONTACT

N

Nicolas Broc, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here